机译:Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Division of Hematology,Sylvester Comprehensive Cancer Center;
Department of Oncology, Hematology and BMT,University Medical Center of Hamburg‐Eppendorf;
Hospital Clínic, IDIBAPSService d'hématologie Clinique,Centre Hospitalier Universitaire de NantesDepartment of Internal Medicine, Division of Hematology,Ondokuz May?s University Faculty of MedicineDepartment of Haematooncology,University Hospital OstravaDepartment of Haematology,Princess Alexandra Hospital and University of Queensland Medical SchoolYonsei University College of Medicine,Severance HospitalParexelAmgen Inc.Memorial Sloan Kettering Cancer Center;
relapsed or refractory multiple myeloma; proteasome inhibitor; carfilzomib; cytogenetics;